Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024.

Additionally, we found that the AARR of BTD and non-BTD drugs were 15% and 20% respectively, indicating a decreasing trend in treatment costs over years for both BTD and non-BTD drugs, which is in contrast to the increase annually in the US. 5 This result is primarily attributed to national drug negotiations established in China since 2016. 8 , 35 , 36 It should be admitted that the median monthly treatment prices for

also in 47,180 other papers